Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Integration of Non-Communicable Disease Services within Primary Health Care

 
Introduction
The Primary Health Care Department at the Ministry of Public Health in collaboration with WHO, launched an initiative for the integration of Non-Communicable Diseases (NCD) program within Primary Health Care centers in Lebanon, in 2012. This initiative aimed at integrating a two-step early detection of Diabetes Mellitus and Hypertension as well as estimating the Total Cardiovascular Risk among beneficiaries aged 40 years and above. The model adopted in this initiative was based on the WHO’s 2012 package of Essential Non-Communicable Diseases interventions for Primary Health Care.
The two-step screening model consists of administering initially a screening tool by the health care workers whether in the setting of the health center or in the community. Step 1 consists of using this tool which is in the form of a questionnaire that tackles information related to the beneficiaries. The health care worker would then calculate the total cardiovascular risk for the beneficiary (using the WHO/International Society of Hypertension –WHO/ISH- risk prediction charts) and would refer him/her to the next step (Step 2) in case the total cardiovascular risk was greater than 10% or there was a previous history of diabetes or hypertension. Step 2 involves performing a set of laboratory tests and a referral to the treating physician for calculation of the final cardiovascular risk.
 
Development of the Non-Communicable Disease Program
The program has passed through many phases, in each phase many centers were trained on implementing and using the NCD programs tools and protocols. All the centers within the Primary Healthcare network were trained on NCD within the time period 2013 to 2017. Training sessions were done on regular basis including 25 centers per session. The training included the healthcare workers, nursing staff, administrative staff and physicians.
 
Continuous Support
In order to maintain the sustainability of the program, POINT OF CARE testing machines for NCD screening were distributed to all involved Primary Health Care centers.
Furthermore, to sustain the accuracy of the data entered daily by the centers, an NCD e module was developed by the IT MoPH department on the Health Information System to aid the centers to enter all the NCD related data and perform the calculations necessary for diagnosis of cardiovascular risks.
The MoPH encourages the Primary Health Care centers in Lebanon to organize outreach activities, events and campaigns to raise the awareness on health factors associated with cardiovascular diseases (CVDs), such as obesity, lack of physical activity and smoking (tobacco-use). MoPH provides educational material to support these activities.
 
    ...
    6
    ...
ATC Name B/G Ingredients Dosage Form Price
J01DD04 LEBACEF G Ceftriaxone (sodium) - 1g, Lidocaine (ampoule) - 1g Injectable powder for solution+diluent 568,253 L.L
N03AX14 LEVIPHAR G Levetiracetam - 1000mg 1000mg Tablet, film coated 2,212,861 L.L
N06AB04 LECITAL 40 G Citalopram - 40mg 40mg Caplet 1,761,778 L.L
J01DD04 LEBACEF G Ceftriaxone (sodium) - 1g 1g Injectable powder for solution 5,793,881 L.L
N03AX14 LEVIPRAM 1000 G Levetiracetam - 1000mg 1000mg Tablet, film coated 1,663,805 L.L
J01DD04 LEBACEF G Ceftriaxone (sodium) - 1g 1g Injectable powder for solution+diluent 508,100 L.L
A03CA02 LIBROCOL G Chlordiazepoxide - 5mg, Clidinium bromide - 2.5mg Tablet 338,648 L.L
J01DD04 LEBACEF G Ceftriaxone - 1g 1g Injectable sterile powder for solution + lidocaine solvent 508,100 L.L
L04AA27 LYXIA G Fingolimod Hydrochloride - 0.25mg 0.5mg Capsule, hard 32,406,715 L.L
N03AX14 LEPITAM G Levetiracetam - 100mg/ml 100mg/ml Solution 1,336,163 L.L
J01DD04 LEBACEF G Ceftriaxone - 1g 1g Injectable sterile powder for solution + lidocaine solvent 508,100 L.L
N03AX14 LEVETIRACETAM ARROW G Levetiracetam - 100mg/ml 100mg/ml Solution 1,639,488 L.L
J01DD04 LEBACEF G Ceftriaxone (sodium) - 1g 1g Injectable powder for solution+diluent 508,100 L.L
N03AX14 LEVETRIMED G Levetiracetam - 100mg/ml 100mg/ml Solution 1,336,163 L.L
R06AE09 LEVOTREX G Levocetirizine dihydrochloride - 5mg 5mg Tablet, film coated 447,948 L.L
J01DD04 LEBACEF G Ceftriaxone (sodium) - 1g 1g Injectable powder for solution 5,793,881 L.L
N03AX14 LEVIPRAM G Levetiracetam - 100mg/ml 100mg/ml Solution 1,285,609 L.L
R06AE09 LIVIDA G Levocetirizine dihydrochloride - 5mg 5mg Tablet, film coated 447,948 L.L
J01DD04 LEBACEF G Ceftriaxone (sodium) - 1g 1g Injectable powder for solution+diluent 643,765 L.L
A10BB09 LOWZID XR G Gliclazide - 60mg 60mg Tablet, extended release 309,724 L.L
J01DD04 LEBACEF G Ceftriaxone (sodium) - 1g, Lidocaine (ampoule) - 1g Injectable powder for solution+diluent 568,253 L.L
N03AX14 LEVETIRACETAM ARROW LAB G Levetiracetam - 500mg/5ml 100mg/ml Injectable solution 8,099,378 L.L
J01DD04 LEBACEF G Ceftriaxone (sodium) - 1g 1g Injectable powder for solution 5,793,881 L.L
N03AX14 LEVIPRAM IV G Levetiracetam - 500mg/100ml 500mg/100ml Injectable solution 1,869,733 L.L
D01AE15 LAMIFEN G Terbinafine HCl - 1% 1% Cream 350,743 L.L
N03AX14 LEVIPRAM IV G Levetiracetam - 1000mg/100ml 1000mg/100ml Injectable solution 2,911,659 L.L
B05BA02 LIPIDEM G Triglycerides, Medium Chain - 100g/500ml, Soya bean oil - 80g/500ml, Omega-3 acid triglicerides - 20g/500ml Injectable emulsion 2,486,109 L.L
D01AE15 LAMINOX G Terbinafine HCl - 10mg/g 10mg/g Cream 453,067 L.L
N03AX18 LACOSAMIDE ARROW G Lacosamide - 50mg 50mg Tablet, film coated, scored 1,679,803 L.L
N03AX18 LACOSAMIDE/GENEPHARM G Lacosamide - 50mg 50mg Tablet 614,136 L.L
    ...
    6
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026